Idioma:

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease

de Franciscis, Stefano ; Gallelli, Luca ; Battaglia, Luigi ; Molinari, Vincenzo ; Montemurro, Rossella ; Stillitano, Domenico M. ; Buffone, Gianluca ; Serra, Raffaele

International wound journal, 2015-06, Vol.12 (3), p.250-253 [Periódico revisado por pares]

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease
Autor: de Franciscis, Stefano ; Gallelli, Luca ; Battaglia, Luigi ; Molinari, Vincenzo ; Montemurro, Rossella ; Stillitano, Domenico M. ; Buffone, Gianluca ; Serra, Raffaele
Assuntos: Aged ; Cilostazol ; Diabetic foot ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Foot Ulcer - enzymology ; Foot Ulcer - etiology ; Foot Ulcer - prevention & control ; Humans ; Intermittent claudication ; Intermittent Claudication - complications ; Intermittent Claudication - etiology ; Male ; Matrix Metalloproteinase 9 - blood ; Metalloproteinase-9 ; Middle Aged ; Original ; Peripheral vascular disease ; Retrospective Studies ; Tetrazoles - administration & dosage ; Treatment Outcome ; Vasodilator Agents - administration & dosage
É parte de: International wound journal, 2015-06, Vol.12 (3), p.250-253
Notas: ArticleID:IWJ12085
ark:/67375/WNG-7GWD5GHB-J
istex:789005743DEB1546B7A31A266920AB414B908E15
Descrição: Diabetic patients are at high risk of foot ulcerations that may lead to limb amputations with important socio‐economic impact. Peripheral vascular disease may be frequently associated in diabetes mellitus type II with its main symptom, intermittent claudication. Many studies reported the known efficacy of cilostazol in treating vascular claudication. Metalloproteinase‐9 (MMP‐9) seems to be a biochemical marker implicated in chronic wounds and in particular in diabetic foot ulcers. Cilostazol appears to have a lowering effect on MMP‐9 levels and this may suggest a beneficial effect in order to prevent or retard the onset of foot ulcer in diabetic patients. In our study, two groups of diabetic patients with peripheral vascular disease were divided into two groups according to the presence of claudication in order to receive cilostazol. Group A (31 patients without claudication) were not eligible to receive cilostazol whereas Group B (47 patients with claudication) received cilostazol administration for 24 weeks (100 mg orally twice daily). Median follow up was of 16 months. During the follow up, 4·25% of patients of Group B and 35·48% of patients of Group A (P < 0·01) showed onset of foot ulceration. Although further randomised and controlled studies are required cilostazol seems to show beneficial effects for primary prevention of diabetic foot ulcers.
Editor: Oxford, UK: Blackwell Publishing Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease

de Franciscis, Stefano ; Gallelli, Luca ; Battaglia, Luigi ; Molinari, Vincenzo ; Montemurro, Rossella ; Stillitano, Domenico M. ; Buffone, Gianluca ; Serra, Raffaele

Oxford, UK: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.